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A Narrative Review of the Anti-Hyperglycemic and Satiating
Effects of Fish Protein Hydrolysates and Their Bioactive
Peptides
Shaun J. Sharkey,* Pádraigín A. Harnedy-Rothwell, Philip J. Allsopp, Lynsey E. Hollywood,
Richard J. FitzGerald, and Finbarr P. M. O’Harte
Prevalence of type 2 diabetes and overweight/obesity are increasing globally.
Food supplementation as a preventative option has become an attractive
option in comparison to increased pharmacotherapy dependency.
Hydrolysates of fish processing waste and by-products have become
particularly interesting in a climate of increased food wastage awareness and
are rapidly gaining traction in food research. This review summarizes the
available research so far on the potential effect of these hydrolysates on
diabetes and appetite suppression. Scopus and Web of Science are searched
using eight keywords (fish, hydrolysate, peptides, satiating, insulinotropic,
incretin, anti-obesity, DPP-4 [dipeptidylpeptidase-4/IV]) returning a total of
2549 results. Following exclusion criteria (repeated appearances, non-fish
marine sources [e.g., macroalgae], and irrelevant bioactivities [e.g.,
immunomodulatory, anti-thrombotic]), 44 relevant publications are included
in this review. Stimulation of hormone secretion, regulation of glucose uptake,
anorexigenic potential, identified mechanisms of action, and research
conducted on the most potent bioactive peptides identified within these
hydrolysates are all specifically addressed. Results of this review conclude
that despite wide methodological variation between studies, there is
significant potential for the application of fish protein hydrolysates in the
management of bodyweight and hyperglycemia.
1. Introduction
Protein is the primary source of amino acids and an important
source of energy within the diet. In addition to this basic
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nutrition, proteins contain motifs that
may possess bioactivity. A large focus of
recent food science research has been
the identification of various bioactivities
in otherwise low-value protein sources
for potential application as a functional
food ingredient.[1] Thus, there has been
a significant amount of research un-
dertaken to mine for bioactive peptides
from hydrolysates of various sources
of protein. These protein sources in-
clude milk whey and casein, shellfish,
egg, wheat, fish, and soybean amongst
others.[2–5] From these various sources,
there has been a wide range of bioac-
tivities reported including anti-cancer,
mineral-binding, immunomodula-
tory, osteoprotective, antimicrobial,
antihypertensive, anti-inflammatory,
anti-diabetic, and anorexigenic capabili-
ties. When combined with the promising
techno-functional properties which
some proteins exhibit, such as high
solubility, good emulsifying capacity and
stability, oil binding, and water holding
capacity,[6,7] these have become an ex-
tremely promising source of ingredients
for functional food applications.
Of all the sources which have been investigated so far, dairy
proteins such as whey and casein have likely been the most
heavily studied.[8–10] Fish/marine products have also become
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promising protein sources, as the application of fish protein
sources as bioactive ingredients would simultaneously improve
the quality of dietary protein, whilst also alleviating some of
the excess wastage associated with the fishing industry and in-
creasing the value of low-value fish now landed due to EU
regulations.[11,12] This is reflected in the increase in availability
of fish hydrolysate products commercially (e.g., Nutripeptin by
Copalis). Despite a growing body of research on the anti-diabetic
and anti-obesogenic effect of fish proteins, to the best of our
knowledge there has been little consolidation of this data. This
prompted the current analysis which aims to specifically review
the current available literature on the effectiveness of fish pep-
tides for alleviating hyperglycemia and obesity.
1.1. The Production of Fish Protein Hydrolysates (FPH)
As mentioned above, much of the bioactivity identification has
been carried out in fish proteins which have been modified
through hydrolysis. The production of peptides with anti-diabetic
and anorexigenic properties has primarily been through either
enzymatic or acid hydrolysis, with research often focusing on
peptides <3 kDa. This is partially due to the improved gastroin-
testinal stability of these peptides compared to the native pro-
teins which are commonly degraded by acid hydrolysis and en-
zymes present in the gastrointestinal tract.[13,14] Furthermore,
previously identified fish hydrolysate-derived peptides with anti-
diabetic activity have been <1.7 kDa.[15–17] By producing hy-
drolysates using enzymes under controlled conditions, the pos-
sibility of variable bioactivity is reduced; however, this does not
completely eliminate variation as there may still be some vari-
ation between hydrolysate batches. The advantage of enzymatic
hydrolysis over, for example, acid or microbial hydrolysis, is the
relatively short time required to produce a high degree of hydrol-
ysis. The resulting short peptides are believed to be more resis-
tant to gastrointestinal digestion than intact proteins.[17–19] This
makes themofmuch greater interest for application in functional
foods as well as for potential pharmacotherapeutic uses.
The peptides generated during hydrolysis depend to a large ex-
tent on the specificity of the proteolytic enzyme(s) used, hydrol-
ysis temperature, pH, and enzyme/substrate ratio.[20] For exam-
ple, many hydrolysates are the result of sequential hydrolysis in
which an endopeptidase (a peptidase which will not cleave pep-
tides to singular amino acids) is used first followed by later ad-
dition of an exopeptidase (a peptidase which will create smaller
peptides and cleave single amino acids from the end of peptide
chains).[21] Given the wide variety of enzyme choices to be consid-
ered depending on the primary desired outcome (small peptides,
mid-length peptides, etc.) and the use of enzymes which can also
de-bitter proteins and create better flavors (e.g., Flavourzyme),
there are abundant possible permutations of peptides which can
be produced as a result of the hydrolysis process and this is re-
flected in the variability of the data presented herein and differ-
ences in dosages used.
2. Search Procedure
Two databases were employed for construction of this re-
view: Scopus (https://www.scopus.com) and Web of Science
Keywords (n=8) searched in 
relevant databases. 2,549 
documents found and title 
screened.
Relevant citations identified 
(n=113) from title screening.
Citations relevant to diabetes 
and obesity (n=79). 
Exclusively fish hydrolysate 
references (n = 44).
Excluded citations (n=35).
Excluded citations (n=34).
Excluded citations (n=2,436).
Exclusion criteria:
- non-fish proteins
- not anti-hyperglycaemic/satiating study
- Duplication
Figure 1. Summary of search procedure used for identification of relevant
literature.
(http://apps.webofknowledge.com). All searches were carried
out before August 12, 2020. Eight keywords were chosen for
searching after consideration of terms most relevant to the area
of interest; fish, hydrolysates, peptides, satiating, insulinotropic,
incretin, anti-obesity, DPP-4 (dipeptidylpeptidase-4/IV). When
searching, the words fish AND hydrolysates were always used,
with a third interchangeable word chosen from one of the re-
maining six. In total, this resulted in 2549 results, which were re-
fined to 113 possibly relevant citations. Publications which used
other marine material (e.g., macroalgae) or did not specifically
deal with anti-diabetic/satiating activity were excluded. Further-
more, many publications appeared more than once throughout
the searches and numbers were reduced significantly when
duplicates were removed. Following this exclusion process, 44
manuscripts were deemed sufficiently relevant to the theme of
this review. This search process is summarized in Figure 1.
3. Anti-Hyperglycaemic Potential of Fish Protein
Hydrolysates
Diabetes is a severe metabolic disorder which is estimated to
affect 451 million people worldwide.[22] Type 2 insulin-resistant
diabetes mellitus (T2DM) accounts for ≈90% of all cases, and is
characterized by impaired insulin secretion, increased hepatic
glucose production, and decreased insulin action. As direct
use of insulin/stimulation of insulin secretion may cause hy-
poglycemia and further decrease in insulin sensitivity, many
pharmacological treatments have recently focused on the de-
velopment of incretin mimetics and prolonging the action of
endogenous incretin hormones.[23–25] The prevalence of diabetes
is rapidly increasing worldwide, and despite the increase in
Mol. Nutr. Food Res. 2020, 2000403 2000403 (2 of 10) © 2020 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH GmbH
www.advancedsciencenews.com www.mnf-journal.com
Table 1. Summary of research on bioactivities from fish hydrolysates relevant to hyperglycaemia.
Source Study type Effect Reference
Alaska pollock
a)
In vitro IC50 ≥ 0.8 mg mL
−1 [96]
Atlantic salmon
a,b)
In vitro ↑ GLP-1 secretion, ↑ insulin secretion [32]
Atlantic cod Human ↓ Postprandial plasma insulin.↔ plasma glucose and
GLP-1
[35]
Atlantic salmon
a)
In vivo ↓ Postprandial blood glucose and plasma DPP-4 activity. ↑
plasma insulin and insulin:glucagon ratio
[48]
Atlantic salmon
b)
In vitro IC50 ≥ 0.3 mg mL
−1 [97]
Atlantic salmon
a)
In vitro IC50 ≥ 0.08 mg mL
−1 [98]
Barbel
a)
In vitro IC50 - 2.21 mg mL
−1 [99]
Bester sturgeon
a,c)
In vivo ↑ Glucose tolerance [79]
Blue whiting
d)
In vitro and in vivo ↑ GLP-1 secretion, ↑ insulin secretion. ↑ glucose tolerance
after 90 min
[31]
Boarfish
e)
In vitro and in vivo ↑ Insulin secretion and GLP-1 secretion. IC50: 1.18 mg
mL−1. ↑glucose tolerance
[33]
Cod Human ↔ Insulin, glucose, and GLP-1 after 8 weeks [91]
Cod Human ↔ insulin, glucose, and GLP-1 [90]
Green crab
e)
In vitro ↑ GLP-1 release, and DPP-4/𝛼-amylase inhibition [100]
Halibut, hake, tilapia, and milkfish
a)
In vitro and in vivo ↓ ≤55% in DPP-4 activity by peptides ≤1.5 kDa (derived
from Tilapia skin). ↓plasma DPP-4 activity after 30 days,
↑ plasma insulin, active GLP-1, and postprandial
glycemic control
[41]
Herring
d)
and salmon
c)
In vivo ↑ Glucose tolerance after 22 days w/ salmon [68]
Herring, salmon, and cod Human ↑ Glucose tolerance after 90 min [92]
Greater weever
d)
In vitro IC50 ≥ 0.38 mg mL
−1 [101]
Marine collagen peptides
e)
Human ↑ Fasting blood glucose and insulin, GHbA1c, and insulin
sensitivity
[51]
Portuguese oyster
e)
In vitro 45% DPP-4 inhibition at 2 mg mL−1 [102]
Rainbow trout
a)
In vitro ≤44% DPP-4 inhibition by peptides <3 kDa [103]
Rainbow trout
c)
In vitro IC50 ≥ 1.23 mg mL
−1 [104]
Salmon
c)
In vitro ↑ Glucose uptake [50]
Sardine
d)
In vitro IC50 ≥ 1.83 mg mL
−1 [105]
Skate
a)
In vivo ↓ Plasma glucose, insulin and insulin resistance [87]
Tilapia
a)
In vivo ↑ Glycemic control, when given orally or i.p. ↑ plasma
insulin at 3 g kg−1
[34]
Unicorn leatherjacket
a)
In vitro ≤50% 𝛼-amylase inhibition [106]
IC50, concentration of condition required to inhibit DPP-4 activity by 50%; BW, bodyweight. Superscript letters indicate the source of the hydrolysate;
a)Skin; b)Trimmings;
c)Bone; d)Muscle; e)Meat. Lack of superscript letter indicates source was not clarified by the authors.
efficacy and longevity of pharmaceutical treatments, these do
little to curb the rise in prevalence.[25,26] Dietary strategies are
becoming increasingly relevant for management and prevention
of these disorders. Previously, research has shown that acute co-
ingestion of protein with a glucose/carbohydrate load improves
postprandial glycemic parameters.[27–29]
3.1. Glycemic Control through Hormone Secretion
Some of the improvement in glycemic parameters with fish
hydrolysates has been observed to happen through hor-
mone secretion—promoting insulin secretion, inhibition of
dipeptidylpeptidase-4 (DPP-4) enzyme activity (for extension of
endogenous incretin hormone half-life), and secretion of the
incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP). For example, it
has been well established from in vitro studies that many fish
protein hydrolysates (FPH) contain potent DPP-4 inhibiting
motifs (summarized in Table 1). The inhibition of DPP-4 and
prolongation of GLP-1 half-life is of greater interest in the devel-
opment of functional foods recently as a statement from EFSA
concluded that a reduction in post-prandial glucose response
“may be considered a beneficial physiological effect as long
as insulin responses are not disproportionally increased”.[30]
FPH were found to cause an increase in insulin secretion in
vitro by Harnedy et al.[31,32] and Parthsarathy et al.[33] Further-
more, Parthsarathy and colleagues and Harnedy et al. showed
a significant increase in plasma insulin in healthy mice.[31,33]
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An increase in plasma insulin was also shown by Iba et al.[34];
however, this involved a very high dose (3 g kg−1 bodyweight)
which may be difficult to achieve when translating this to human
studies. Despite these promising in vivo results, none of the
human studies with fish hydrolysates have shown an increase
in plasma insulin, while one study showed a decrease in plasma
insulin.[35] Research in dairy hydrolysates has followed a similar
focus of investigating the impact of insulin on glycemic control
improvement.[36–38] If fish hydrolysates were to stimulate insulin
secretion through secretion of endogenous incretin hormones or
prolongation of half-life, there would be no risk of hypoglycemia
as the insulinotropic action of incretin hormones is dependent
on the prevailing blood glucose concentration.
Various studies have investigated GLP-1 secretion, both in
vitro and in vivo,[32,39–41] with particular attention being drawn to
the work ofWang and colleagues[41] which is the only study inves-
tigating the effects of chronic administration on plasma GLP-1,
and showed a significant increase in active GLP-1 with multiple
skin gelatin hydrolysates. However, no study has yet examined
how the peptides are eliciting this effect. For example, free amino
acids such as glutamine are known to potently stimulate incretin
hormone secretion from intestinal cells,[42,43] but it is not known
if the increased hormone release seen with these FPH is due to
further peptide breakdown to free amino acids, or if the peptides
remain intact and bioactive when passing through the gastroin-
testinal tract. This point is reinforced by the work of Harnedy
et al.[31,32] where a simulated gastrointestinal digestion model
showed some improved bioactivities, but again it is unclear if this
was due to the formation of potentiallymore potent bioactive pep-
tide fragments or increased free amino acid release. Production
of more bioactive peptide fragments could prove an interesting
development for future uses of such peptides, as the chronic
effect of a more stable peptide which remains intact will likely
be much more effective than that of free amino acids which will
be excreted relatively quickly. Furthermore, in the case of T2DM,
ingestion of free amino acids in the fasting state may encourage
hyperglycemia through an increase in substrate availability for
gluconeogenesis.[44]
The use of DPP-4 inhibitors has rapidly grown in popularity
partly due to being an orally available treatment.[45,46] This is also
reflected in the level of research conducted into food-derived
peptides as DPP-4 inhibitors.[47,48] There are numerous studies
examining the in vitro potency of FPH as DPP-4 inhibitors (sum-
marized in Table 1). Although the main body of this research
has been in vitro models, there are limited numbers of in vivo
models examining plasma DPP-4 enzyme activity. However, both
Hsieh et al.[49] and Wang et al.[42] showed a promising reduction
in plasma DPP-4 activity after long-term hydrolysate administra-
tion. While it is interesting to see that the DPP-4 inhibition does
translate to animal models, the dosage used was relatively high
(300 mg per day and 750 mg kg−1 BW per day, respectively) thus
it may be difficult to see a corresponding reduction translating
to human studies. Furthermore, many studies have shown
reduction in blood glucose but have not specifically measured
plasma DPP-4 activity. Some of the effect witnessed may be due
to reduced DPP-4 activity but this potential mechanism was
not measured directly and further research is needed in this
area.
3.2. Regulation of Glucose Uptake
Although some of the anti-diabetic effectmay be due to themech-
anisms discussed in Section 3.1, there is also a promising body
of research demonstrating the ability of FPH in enhancing glu-
cose uptake and reducing lipid accumulation in vitro. Increased
glucose uptake is a vital part of blood glucose control in T2DM,
as there is increased hepatic glucose production and associated
elevated blood glucose, resulting in glucotoxicity and eventually
𝛽-cell dysfunction.[50] A fractionated hydrolysate of salmon frame
exhibited glucose uptake equal to that of insulin in rat skeletal
muscle (L6) cells.[51] Harnedy et al. also showed an enhance-
ment in glucose uptake in mouse adipose (3T3-L1) cells with
both salmon and blue whiting protein hydrolysates.[31,32] Fur-
thermore, Zhu et al., while showing no significant change in
plasma insulin in diabetic patients, showed an improvement in
insulin sensitivity with 6 weeks of treatment with marine colla-
gen peptides.[52] However, the understanding of themechanisms
of action of glucose uptake by FPH is limited. Insulin receptor
(IR), insulin receptor substrate-1/2 (IRS - 1/2), phosphoinositide-
3-kinase (PI3K), and protein kinase B (Akt) all play important
regulatory roles in glycemic control through increasing insulin
sensitivity. None of the studies carried out to date have exam-
ined upregulation of these pathways, nor have changes in in-
sulin sensitivity been reported in any of the in vivo studies. Ayabe
et al. showed an in vitro increase in glucose uptake and in vivo
plasma glucose reduction but did not further investigate the in
vivo mechanism of action.[52] Understanding the extent of glu-
cose uptake enhancement in animal models will add further
weight to the in vitro studies already carried out. Furthermore,
this analysis combined with information regarding the upregula-
tion of glucose transporters such as GLUT2 and GLUT4 (which
are primary regulators of glucose uptake) could play a key role
in understanding the wider effect of these hydrolysates on blood
glucose homeostasis.
4. Anorexigenic Potential of Fish Protein
Hydrolysates
Obesity is another chronic non-communicable metabolic disease
which affects 650 million people globally.[53] There are a wide
number of obesity-related co-morbidities, including cardiovascu-
lar diseases, cancer, and T2DM.[54] Obesity accounts for ≈80%
of risk of development of T2DM.[55,56] Inflammation, adipokines
and overaccumulation of lipids in pancreatic, liver, and muscle
tissue is thought to play a role in the molecular link between de-
velopment of both obesity and T2DM.[57,58] The above are all ac-
centuating factors of the 𝛽-cell dysfunction and insulin resistance
commonly associated with T2DM.[50,58,59]
Many of the entero-insular axis hormones which play a role in
diabetes also play a role in appetite control, such as GLP-1, GIP,
cholecystokinin (CCK), and peptide-YY (PYY).[60–62] However,
pharmaceutical targeting of some of these hormones (namely
CCK and PYY) has been largely unsuccessful due to receptor
expression in the nervous system, resulting in increased men-
tal health concerns.[63,64] This has made functional foods an at-
tractive option as the adverse effects seen with high dose phar-
macotherapies should not occur in lower dose oral treatments,
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Table 2. Summary of research on bioactivities from fish hydrolysates relevant to obesity.
Source Study type Effect Reference
Alaskan pollock
b)
In vivo ↓Weight gain over 3 days, and in NPY and AgRP expression [66]
Blue whiting
b)
brown shrimp
c)
In vitro ↑ CCK secretion [86]
Blue whiting
b)
In vitro and in vivo ↑ GLP-1 and CCK secretion. ↓ food intake and weight gain. ↑
plasma GLP-1 and CCK
[39]
Common cuttlefish
d)
In vitro IC50 of 1 mg mL
−1. ↑ GLP-1 and CCK secretion [40]
Common smoothhound
b)
In vivo ↓Weight gain after 21 days.↔ food intake, plasma insulin
and CCK
[65]
Ocellate spot skate
a)
In vivo ↓ Serum leptin [107]
Skate
a)
Human ↓ Body fat and body fat mass [108]
Yellow catfish In vivo ↓Weight gain. ↓ total cholesterol at 500 mg kg−1 BW [88]
Blue whiting
b)
Human ↓ Desire to eat something sweet after 90 min (breakfast at
60 min after capsules).↔ plasma glucose, insulin, CCK,
and GLP-1
[94]
Blue whiting
b)
Human ↓ Bodyweight, BMI, waist hip, and thigh circumference after
45 days
[95]
Cod Human ↔ Plasma ghrelin and satiety/fullness scores [89]
LDL, low-density lipoprotein; TG, triglycerides; NEFA, non-esterified fatty acids; HDL, high-density lipoprotein. Superscript letters indicate the source of the hydrolysate; a)Skin;
b)Muscle; c)Head; d)Viscera. Lack of superscript letter indicates source was not clarified by the authors.
but they may still alleviate symptoms if used as a preventative
measure or early-stage treatment in combination with lifestyle
change. Although the complications of obesity alleviate if the in-
dividual loses weight, it is often difficult to lose weight and re-
main motivated to maintain this weight loss. Thus, it is impor-
tant to identify viable options (e.g., functional foods) which may
make this weight loss more achievable and sustainable.
The anorexigenic effect of FPH has received markedly less at-
tention than studies on anti-diabetic action, as represented in
Table 2. Of the limited in vivo studies which have been carried
out, only one has shown an improvement in circulating GLP-1
and CCK, while another has shown that there was no significant
change.[40,65] Despite this, many FPH have shown reductions in
weight gain both in vivo and in human studies; however, the
mechanism through which this is facilitated is poorly character-
ized. Data from Mizushige et al. interestingly showed a decrease
in expression of hypothalamic neuropeptide-Y and agouti-related
protein mRNA, both of which play orexigenic roles in brain ap-
petite regulating centers.[66] However, they also showed no sig-
nificant increase in pro-opiomelanocortin (POMC) or cocaine
and amphetamine-related transcript (CART) mRNA expression,
which play an anorexigenic role.[66] These data suggest that the
decrease in weight gain may be due to antagonism of orexigenic
factors rather than enhancement of anorexigenic factors; how-
ever, this a singular study and more research is required to better
understand these effects. Some of the reduction in food intake
may also be due to delayed gastric emptying through protein-
carbohydrate binding.[7] In addition, this action on gastric emp-
tying could be either direct or indirect via DPP-4 inhibition and
subsequent enhancement of GLP-1 release.
It is also important to note that although not related to ap-
petite regulation by intestinal hormones,many hydrolysates have
shown significant improvements in lipid profiles in both in vivo
animal and human studies.[51,66–68] Lipid profile plays a role in
the pathogenesis of T2DM and obesity, and improvement in lipid
profile is an important outcome for reduction in cardiovascular
disease risk, which is a common co-morbidity of both obesity and
T2DM.
5. Isolation of Bioactive Peptides from Fish Protein
Hydrolysates
Given the large body of research on crude fish hydrolysates, there
is relatively little work focusing on the isolated peptides which
have been identified within these hydrolysates. Identification
of bioactive peptides within these hydrolysates is useful for
potential pharmacotherapeutic uses. For example, if a specific
peptide fraction exhibits greater bioactivity than a crude hy-
drolysate, then use of this single fraction in a foodstuff (oral
supplement) could make the resulting bioactivity more potent
due to concentration of the bioactive fractions and removal of
potential antagonistic peptides. For pharmacotherapeutic use,
the identification of novel specific peptides is an attractive route
as peptide therapeutics are rapidly increasing in popularity as
discussed previously; however, larger peptides typically have
very poor oral bioavailability.[69] The small peptides present in
these hydrolysates may have improved oral bioavailability so
modification of these peptides to enhance bioactivity, when
combined with good oral bioactivity, would be of great interest as
a future therapeutic option.[70] In a clinical setting, the ability of
these peptides to compare to current peptide treatments (such as
Semaglutide [Ozempic], a once-weekly treatment) is unlikely, as
these are often heavily modified peptides; however, use of these
orally available peptides in a concentrated form could represent
a viable option in early-stage/prediabetes treatment where the
use of such expensive treatments is not warranted. Furthermore,
these peptides could also be modified in future studies which
could produce effects similar to some current peptide treatments,
and identification of bioactive sequences sheds some light on
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Table 3. Summary of available literature on the effects of fish-hydrolysate-derived peptides on hyperglycaemia and obesity.
Source Study type Peptide sequence Mw [Da] Effect Reference
Alaskan pollock In vitro and in vivo QWR 488.53 ↑ Glucose uptake. ↓ plasma glucose
with hydrolysate and peptide
[52]
Atlantic salmon
a)
In vitro GPAE 372 IC50 ≥ 41.9 µm [16]
GPGA 300.29
Atlantic salmon
a)
In vitro YYGYTGAFR 1096.49 IC50 ≥ 128.7 µm [109]
LDKVFR 776.45
VLATSGPG 700.37
Boarfish
b)
In vitro IPVDM 574.29 IC50 ≥ 21.7 µm [85]
APIT 401.24 ↑ Insulin secretion
VPTP 413.23
GPIN 400.22
LPVYD 303.66
LPVDM 574.29
APLER 293.17
IPGA 357.21
GPSL 373.21
GPSI 373.21
APVP 383.23
VPDPR 292.17
APLDK 272.16
APLT 401.23
MPAVP 257.66
GPGI 343.20
GPLN 400.22
PAVP 383.23
GPGL 343.20
LPGA 357.21
AALP 371.23
TPTV 417.27
Silver carp
c)
In vitro IADHFL 714.8 IC50 = 610.1 µm [17]
Fish
a)
In vitro GP(HP) 269.3 IC50 = 2.5 mm [110]
Tuna
d)
In vitro PGVGGPLGPIGPCYE 1412.7 IC50 ≥ 78 µm [15]
CAYQWQRPVDRIR 1690.8
PACGGFYISGRPG 1304.6
IC50, concentration of condition required to inhibit DPP-4 activity by 50%; HP, hydroxyproline. Superscript letters indicate the source of the hydrolysate;
a)Skin; b)Meat;
c)Muscle; d)Whole fish. Lack of superscript letter indicates source was not clarified by the authors.
factors determining the beneficial effects of small molecular
weight peptides.
The key structural components for bioactivity retention are
far from clear; however, in general peptides containing a proline
in the ultimate or penultimate C-terminal position, or the first,
second, third, or fourth position from the N-terminal position
has been found to increase DPP-4 inhibitory activity. This is
enhanced in the presence of other hydrophobic amino acid
residues.[71–73] This area has been reviewed more in-depth
elsewhere.[74] Interestingly, many of the peptides with identi-
fied bioactivities (Table 3) adhere broadly to these hypotheses.
Harnedy-Rothwell et al. identified 22 peptides from boarfish
which exhibited DPP-4 inhibitory activity in vitro and in situ us-
ing a Caco-2 cell model and all sequences contained at least one
proline and the sequences are rich in other hydrophobic amino
acids such as glycine, alanine, leucine, isoleucine, and valine. All
other studies in Table 3 also show an abundance of hydrophobic
amino acids. Most peptides have only been screened in vitro,
and usually to assess DPP-4 inhibitory activity. Many of these
have shown promising bioactivities which correspond with the
bioactivity found in their precursor hydrolysates. Interestingly,
all of the peptides which have been identified thus far are small
peptides, with the largest being 1.7 kDa. This agrees with the
aforementioned evidence in relation to how the protein hydrol-
ysis process produces these smaller peptides which have greater
bioactivity. As peptides which exhibit DPP-4 inhibitory activity
have also often displayed anti-oxidant activity,[74,75] this anti-
oxidant effect could also play a cytoprotective effect on pancreatic
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beta cells.[76] Furthermore, Ben Henda et al.[77] showed some di-
and tri-peptides derived from collagen had anorexigenic benefits
by up to 80% cytotoxicity in white adipose cells, which is the type
of tissue understood to be the primary source ofmany adipokines
involved in the chronic low-grade inflammation associated with
obesity.[78] However, very often the authors did not specify which
specific marine source the peptides were derived from, thus it
could not be included in the tablature associated with this review.
It has also been hypothesized in various published works
that the bioactivity is not dependent on molecular weight, but
rather the amino acid sequence. For example, Sasaoka et al.[79]
reported a blood glucose lowering effect of a collagen hydrolysate
from sturgeon by-products. However, peptide sequence analysis
showed a repetitive sequence of Gly-X-Y in each bioactive pep-
tide. This is a commonly occurring sequence in the triple helical
region of collagen, and liberation of these sequences during
hydrolysis results in collagen hydrolysates from various sources
producing consistently potent bioactivity. To date, no specific
key structural components have been identified in hydrolysates
produced from other fish components such as muscle or bone.
This hypothesis is further supported by Mizushige et al.[66] who
reported a reduction in food intake with Alaskan pollock protein
hydrolysate, whereas there was an increase in appetite when
mice were presented with a 10 amino-acid long soybean-derived
peptide.[80] However, no specific peptide sequences were iden-
tified by Mizushuge et al. to confirm sequence differences.[66]
Furthermore, identification of structure-activity relationships is
further limited by different structural characteristics resulting in
different “primary” bioactivities, that is, the relevant structural
properties which affect DPP-4 inhibition may be different to
those relevant to insulin or GLP-1 secretion.
One area which has been largely overlooked by the existing
literature is the oral bioavailability of these peptides. Sontakke
and colleagues have studied how collagen-derived peptides are
crossing the intestinal layer in vitro through use of the Caco-2 cell
model, which showed that a tri-peptide (GPH) was able to cross
the intestinal layer much more efficiently than a di-peptide (PH)
derived from breakdown of the original tri-peptide.[81] Further-
more, these workers supported this finding by measuring GPH
levels in plasma after oral presentation to mice which reached
maximum levels within 1 h and returned to basal levels within
3 h, indicating that there was no postprandial response causing
synthesis of endogenous GPH. By showing that GPH can more
effectively cross the intestinal layer than PH, it implies that the
affinity of peptides for active transporters in the intestinal layer
plays a greater role in oral bioavailability than peptide size when
all peptides are already small. As mentioned above; however, this
has not as yet been studied in FPH-derived peptides and thus fur-
ther research is needed to assess the bioavailability of small pep-
tides. As Caco-2 cells are derived from a colon adenocarcinoma,
they often form tighter junctions than would typically be found
in the duodenumwhere most macromolecules are absorbed. De-
spite this, they are a relatively accurate cell model and have been
used for other food-derived peptides in the past.[82–84]
6. General Discussion
The primary aim of this review was to summarize the available
literature regarding FPH role in preventing hyperglycemia and
increasing satiety, which could have beneficial impact in diabetes
and obesity, respectively. Furthermore, it is the role of this review
to elucidate the mechanisms through which FPHs are exerting
these effects in the available literature. It is important to firstly
address that there are several confounding factors which make
it difficult to draw a consistent conclusion—namely the “source
material” (the fish used will affect resulting bioactivity, as will the
part of the fish used, e.g., muscle, bone, scales, collagen, etc.),
the processing methods/enzymes used, and the dosage concen-
tration/frequency.
To clarify the effects, it is likely easiest to deal with the litera-
ture according to the level of research involved—in vitro, in vivo,
or clinical trials in humans. Naturally, much of the research at
this point is based upon in vitro findings. As previously discussed
in Section 3.1, a large portion of the in vitro research is DPP-4
inhibitory assay-based. Even with the methodological variability
discussed before, FPH are clearly a potent source of DPP-4 in-
hibitory peptides with IC50 values as low as 0.08 mg mL
−1 (from
a salmon gelatin hydrolysate) to 2.21 mg mL−1 (from a barbel
skin gelatin hydrolysate). Furthermore, most identified bioactive
peptides from FPH (Table 3) have exhibited potent DPP-4 in-
hibitory activity, and although it is difficult to directly compare
doses of isolated peptide to that of a crude hydrolysate, it is pos-
sible that many of the isolated peptides are more potent than
the crude hydrolysate. Thus, Harnedy-Rothwell et al. identified
IPVDM as the third-most potent food-derived DPP-4 inhibitor
discovered to date, with an IC50 of 21.7 µm.
[85] Alongside this
strong evidence for DPP-4 inhibitory action, several studies have
also shown FPH to have strong insulin, GLP-1, and CCK release
actions.[31–33,39,40,85,86]
The in vivo efficacy of FPH has also been reasonably well es-
tablished. Acutely, all studies investigating an anti-hyperglycemic
effect of FPH has found a reduction in blood glucose with doses
as low as 50 mg kg−1 bodyweight,[33] and several exhibiting an in-
crease in plasma insulin [33,34] or GLP-1[34]; however, Iba et al.[34]
used extremely high doses of 1.5 g kg−1 and 3 g kg−1 bodyweight
which would be impossible to translate to a human trial. Other
studies have shown the anti-hyperglycemic effect to be evenmore
pronounced in a chronic setting, with the lowest dose used be-
ing 100 mg kg−1 bodyweight.[41,48,68,87] Furthermore, all in vivo
studies investigating the satiating effect of FPH have shown a
decrease in bodyweight or a reduction in weight gain.[39,65,66,88]
These findings are very encouraging, given the wide method-
ological variation between studies discussed previously. Ayabe
et al. also found that a tripeptide derived from Alaskan pollack,
QWR, decreased plasma glucose and improved insulin sensitiv-
ity at 1mg kg−1 BW in vivo, similarly to the precursor hydrolysate,
presumably through enhancement of glucose uptake.[52]
Human trials involving FPH are naturally quite limited, due
to the novelty of the area and dependence upon first finding
a promising bioactive source in vivo. Nevertheless, there have
been multiple studies recently published investigating the anti-
diabetic and satiating effect of a cod protein hydrolysate; however,
there appears to be no significant effect on plasma hormones,
blood glucose, or satiety with one study reporting a reduction in
plasma insulin.[35,89–91] Initially this appears to be due to a very
low dosage regimen (a maximum of 4 g per day) but a sepa-
rate study performed by Hovland et al. showed an effect on glu-
cose tolerance by a cod protein supplement through ingestion of
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2.5 g per day for 8 weeks.[92] The important differentiation be-
tween these studies is likely that Hovland et al. used an unhy-
drolyzed cod protein supplement, highlighting that the bioactiv-
ity of the protein is impacted by the hydrolysis process, and in
this case hydrolysis may have negatively impacted the bioactivity.
It is also possible that as both supplements were prepared by pri-
vate companies in encapsulated/liquid form that other process-
ing activities affected the bioactivity. However, Harnedy-Rothwell
et al. found that the DPP-4 inhibitory activity of a boarfish hy-
drolysates was not affected by heat treatment when prepared in a
tomato-based product.[93] Despite this interesting confliction be-
tween these two research groups, many others have shown more
promising effects. A marine collagen peptide fraction adminis-
tered to T2DM subjects showed marked improvements in fast-
ing blood glucose, HbA1c, and insulin sensitivity.
[51] Two other
studies investigating blue whiting protein hydrolysates showed
beneficial effects on bodyweight, body compositionmarkers, and
satiety scores.[94,95] A trial involving skate skin also showed a re-
duction in bodyweight and fat mass.[87] Generally speaking, hu-
man trials involving FPH have been reasonably successful with
the exception of results from a single cod protein hydrolysate.
To conclude, it is clear that despite the methodological varia-
tion between studies involving FPH, there is significant potential
for use of these hydrolysates in the prevention and management
of bodyweight and hyperglycemia. If thesemethodological issues
can be addressed (potentially by generating comprehensive in
vivo data initially and by determining an effective dose which is
achievable in human trials), then there is likely to be a significant
increase in interest in the use of FPH as a functional ingredient.
Furthermore, many studies have found an effect on bodyweight
or blood glucose but have not been able to conclusively identify
a mechanism of action through which this is achieved. An
increase in prioritizing mechanism of action studies, along with
identification of bioactive peptides could yield much more ef-
fective supplements (by only including the most potent peptide
fractions) and overall improvement in the understanding of
the structural features important for anti-hyperglycemic and
satiating bioactivity.
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